秋水仙碱与围手术期急性肾损伤:COP-AF随机临床试验的子研究
该研究为COP-AF试验的预设肾脏子研究,纳入2947例接受大型非心脏胸科手术的患者,随机分配至秋水仙碱0.5mg每日两次或安慰剂组,用药10天。结果显示,秋水仙碱组围手术期急性肾损伤发生率为4.7%,安慰剂组为4.4%(RR 1.07, 95%CI 0.76-1.50, P=0.72),两组风险无显著差异,且在慢性肾脏病患者中结果一致。
要点
- 秋水仙碱未降低非心脏胸科手术患者围手术期急性肾损伤风险。
- 秋水仙碱组与安慰剂组AKI发生率分别为4.7%和4.4%,风险比1.07。
- 在合并慢性肾脏病的患者中,秋水仙碱对AKI风险无显著影响。
核心结论
- 在接受非心脏胸科手术的患者中,秋水仙碱组与安慰剂组的围手术期急性肾损伤风险无差异。
研究设计与样本
- 研究为COP-AF随机临床试验的预设子研究,纳入2947例55岁以上接受大型非心脏胸科手术的患者,随机1:1分配至秋水仙碱0.5mg口服每日两次或安慰剂组,用药10天。
主要发现
- 秋水仙碱组围手术期AKI发生67例(4.7%),安慰剂组63例(4.4%),风险比(RR)1.07(95%CI 0.76-1.50,P=0.72),风险差(RD)0.3%(95%CI -1.2%至1.8%)。
- 在慢性肾脏病患者中,秋水仙碱与安慰剂相比AKI的风险差为-0.9%,无慢性肾脏病患者中为0.5%(交互作用P=0.62)。
关键数值与推荐
- 围手术期AKI定义为术后48小时内血清肌酐升高≥0.3 mg/dL或术后7天内升高≥50%。
临床怎么用
- 对于接受非心脏胸科手术的患者,围手术期使用秋水仙碱不能降低急性肾损伤风险,不应以肾脏保护为目的处方秋水仙碱。
局限性
- 统计效力有限,无法检测秋水仙碱对需要透析的AKI等小但临床重要效应的影晌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Perioperative inflammation may result in organ injury, including acute kidney injury (AKI). Colchicine, an anti-inflammatory drug, may help protect the organs from inflammation. This clinical trial substudy examined whether colchicine reduced the risk of perioperative AKI compared with placebo. STUDY DESIGN: Prespecified substudy of a placebo-controlled randomized clinical trial. SETTING & PARTICIPANTS: Patients aged 55 years or older undergoing major noncardiac thoracic surgery enrolled in the Colchicine for the Prevention of Perioperative Atrial Fibrillation (COP-AF) trial from 45 centers in 11 countries (2018-2023). Patients were excluded for a history of atrial fibrillation, for taking antiarrhythmic medication, or for a preoperative estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m2. EXPOSURE: Participants were randomized 1:1 to 0.5 mg oral colchicine or placebo, given twice daily for a total of 10 days. Patients, health care providers, data collectors, and outcome adjudicators were masked to the treatment assignment. OUTCOME: Perioperative AKI, defined as an increase in serum creatinine concentration of either ≥0.3 mg/dL within 48 hours of surgery or ≥50% within 7 days of surgery. Alternative definitions of AKI were examined, as was effect modification by pre-existing chronic kidney disease (CKD). RESULTS: Among 3,209 patients enrolled in the main trial, 2,947 were included in this substudy (mean age, 68 years; mean eGFR, 83 mL/min/1.73 m2) and were randomly allocated to receive colchicine (n = 1,476) or placebo (n = 1,471). Perioperative AKI occurred in 67 participants (4.7%) in the colchicine group and in 63 participants (4.4%) in the placebo group (risk ratio [RR], 1.07 [95% CI, 0.76-1.50], P = 0.72; risk difference [RD], 0.3% [95% CI, -1.2% to 1.8%]). The RD of AKI in patients with CKD treated with colchicine versus placebo was -0.9%, and it was 0.5% in those without CKD (interaction P = 0.62). LIMITATIONS: Limited statistical power to detect small clinically important effects on AKI treated with dialysis. CONCLUSIONS: Among patients undergoing noncardiac thoracic surgery, the risk of perioperative AKI did not differ between patients allocated to receive colchicine versus placebo. FUNDING: Grants from academic (Department of Medicine, Western University; Division of Cardiology, McMaster University), government (Canadian Institutes of Health Research; General Research Fund, Research Grants Council, Hong Kong Special Administrative Region, China), and not-for-profit (Accelerating Clinical Trials Consortium; Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; Population Health Research Institute; Hamilton Health Sciences; Hanela Foundation) sources. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03310125. PLAIN-LANGUAGE SUMMARY: Inflammation during and after surgery can lead to organ injury, including acute kidney injury (AKI). Colchicine, an anti-inflammatory drug, may help protect the organs from inflammation. This prespecified kidney substudy of the COP-AF trial (a placebo-controlled, randomized clinical trial of 3,209 patients aged 55 years and older having major noncardiac thoracic surgery), examined the effect of oral colchicine (0.5 mg tablet, taken twice daily starting within 4 hours before surgery for a total of 10 days) on the risk of perioperative AKI. The study found that the risk of perioperative AKI did not differ between patients assigned to receive colchicine versus placebo. The results were consistent for multiple definitions of AKI and in patients with pre-existing chronic kidney disease.
引用
- Garg AX, Cuerden MS, Sontrop JM, et al. Colchicine and Perioperative Acute Kidney Injury: A Substudy of the COP-AF Randomized Clinical Trial. Am J Kidney Dis. 2026. PMID: 42965558. doi:10.1053/j.ajkd.2026.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。